rs2233518
Positions:
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_002528.7(NTHL1):c.116-17C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00188 in 1,598,958 control chromosomes in the GnomAD database, including 40 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★). There are indicators that this mutation may affect the branch point..
Frequency
Genomes: 𝑓 0.0098 ( 21 hom., cov: 32)
Exomes 𝑓: 0.0010 ( 19 hom. )
Consequence
NTHL1
NM_002528.7 intron
NM_002528.7 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.802
Genes affected
NTHL1 (HGNC:8028): (nth like DNA glycosylase 1) The protein encoded by this gene is a DNA N-glycosylase of the endonuclease III family. Like a similar protein in E. coli, the encoded protein has DNA glycosylase activity on DNA substrates containing oxidized pyrimidine residues and has apurinic/apyrimidinic lyase activity. [provided by RefSeq, Oct 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -20 ACMG points.
BP4
This place is a probable branch point but likely benign (scored 2 / 10). Computational evidence support a benign effect (BayesDel_noAF=-0.83).
BP6
Variant 16-2046383-G-A is Benign according to our data. Variant chr16-2046383-G-A is described in ClinVar as [Benign]. Clinvar id is 1284832.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr16-2046383-G-A is described in Lovd as [Benign].
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.0098 (1493/152300) while in subpopulation AFR AF= 0.0341 (1417/41544). AF 95% confidence interval is 0.0326. There are 21 homozygotes in gnomad4. There are 722 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 21 AR gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NTHL1 | NM_002528.7 | c.116-17C>T | intron_variant | ENST00000651570.2 | NP_002519.2 | |||
NTHL1 | XM_047434171.1 | c.-181C>T | 5_prime_UTR_variant | 2/6 | XP_047290127.1 | |||
NTHL1 | NM_001318193.2 | c.116-17C>T | intron_variant | NP_001305122.2 | ||||
NTHL1 | NM_001318194.2 | c.-63-17C>T | intron_variant | NP_001305123.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00978 AC: 1488AN: 152182Hom.: 21 Cov.: 32
GnomAD3 genomes
AF:
AC:
1488
AN:
152182
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00267 AC: 656AN: 245272Hom.: 10 AF XY: 0.00193 AC XY: 257AN XY: 133456
GnomAD3 exomes
AF:
AC:
656
AN:
245272
Hom.:
AF XY:
AC XY:
257
AN XY:
133456
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00105 AC: 1516AN: 1446658Hom.: 19 Cov.: 31 AF XY: 0.000906 AC XY: 650AN XY: 717606
GnomAD4 exome
AF:
AC:
1516
AN:
1446658
Hom.:
Cov.:
31
AF XY:
AC XY:
650
AN XY:
717606
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00980 AC: 1493AN: 152300Hom.: 21 Cov.: 32 AF XY: 0.00969 AC XY: 722AN XY: 74476
GnomAD4 genome
AF:
AC:
1493
AN:
152300
Hom.:
Cov.:
32
AF XY:
AC XY:
722
AN XY:
74476
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
3
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:3
Benign, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Benign, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Benign, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital | Aug 15, 2023 | - - |
not provided Benign:2
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
NTHL1-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Nov 13, 2023 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
BranchPoint Hunter
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at